Biogen discontinues Apellis programs post $5.6B acquisition, reallocating resources to Empaveli and Syfovre. U.S. begins ...

From persevering with a tricky Alzheimer’s program to securing a late-stage CD38-directed antibody and posting encouraging lupus data, Biogen has remained in the news recently—and that’s no accident.

Biogen Canada Inc. is disappointed that negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for SKYCLARYS™ ...

With the passage of another year in the biz, and another slate of company earnings stacked up against one another, Fierce is ...

Teva Pharmaceutical Industries (NYSE:TEVA) has completed the acquisition of Emalex Biosciences, bringing ecopipam, a late stage investigational treatment for pediatric Tourette syndrome with FDA ...

Deutsche Börse Scale Summit June 23, 2026 6:30 AM EDTCompany ParticipantsPascal Klein - Chairman of the Executive Board ...

Researchers are investigating whether treating prodromal symptoms that precede radiologically isolated syndrome can delay or ...

Alzheimer’s drug development now targets tau, neuroinflammation, metabolism, and synaptic dysfunction — expanding beyond amyloid toward precision medicine and combination therapy.

Kneat Solutions, the Limerick-headquartered software company listed in Toronto, has agreed to sell itself to US private equity group Thoma Bravo for 650 million Canadian dollars (€404 million). The ...

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

BOSTON, June 8 (Reuters) - Biogen (BIIB.O), opens new tab has agreed to pay $18.9 million to resolve a lawsuit alleging that it misled investors about the commercial readiness of the pharmaceutical ...